3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
CNS
3
Breast
3
Sarcoma
2
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
4
Pheochromocytoma
2
Paraganglioma
2
Thymoma
1
Sarcoma, Synovial
1
Recurrence
1
Osteosarcoma
1
Neuroblastoma
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
EGFR-Mutated Non-Small-Cell Lung Carcinoma
1
Carcinoid Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
3-Iodobenzylguanidine
3
olaparib
1
lutetium Lu 177 dotatate
1
entrectinib
1
entinostat
1
Pemetrexed
1
Paclitaxel
1
Dexamethasone
1
Calcium Dobesilate
1
Cabergoline
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
olaparib
×
Endocrine
×
Clear all
NCT06607692
2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled